FDA-cleared profile

TeraRecon Cardiovascular.Calcification.CT

Terarecon,Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Automatic coronary-artery calcium plaque segmentation for downstream calcium scoring.

Clinical role
Segmentation and classification support for downstream calcium scoring; adjunctive information only and not a stand-alone diagnostic tool.
Images and patients
CT/CTA · Heart/Coronary Arteries
Key limitation
Keep in mind: Excluded patients include pre-existing cardiac devices/electrodes, established ischemic disease such as grafts, stents, or PTCA, and thoracic metallic devices. Use with GE or Siemens equipment or subsidiaries is recommended; other manufacturers are not recommended. The packet is internally inconsistent about gated status in a comparison paragraph, so gated support is not inferred beyond the non-contrast CT-heart indication.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Automatic coronary-artery calcium plaque segmentation for downstream calcium scoring.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Coronary Arteries Input: Non-contrast CT heart calcium-score studies from adults aged 30 and older, with GE or Siemens equipment or subsidiaries recommended; exclusions include cardiac devices/electrodes, established ischemic disease, and thoracic metallic devices.
  • Who uses it?Intended users: Trained healthcare professionals responsible for patient-management decisions under standard of care.
  • What does the software produce?Output: DICOM result files containing an automatic 3D coronary-calcification mask, vessel classification for LM/LAD/LCX/RCA, and Agatston category classification for downstream scoring; the device does not output the Agatston score directly or alter the original data.
  • What is its most important limitation?Key limitation: Excluded patients include pre-existing cardiac devices/electrodes, established ischemic disease such as grafts, stents, or PTCA, and thoracic metallic devices. Use with GE or Siemens equipment or subsidiaries is recommended; other manufacturers are not recommended. The packet is internally inconsistent about gated status in a comparison paragraph, so gated support is not inferred beyond the non-contrast CT-heart indication.

Clinical takeaway. Clinical role: Automatic coronary-artery calcium plaque segmentation for downstream calcium scoring.

Evidence takeaway. Evidence from the reviewed source record: FDA retrospective cohort study included 422 adults aged 30 and older with non-contrast calcium-score CT and heart coverage; ground truth used three annotators and majority voting, with at least 50% of ground-truth data from multiple U.S. locations. FDA testing used segmentation Dice, Agatston-category accuracy, vessel-classification Dice, precision/recall, and agreement analyses. The packet states acceptance criteria of at least 80% accuracy/Dice with a 95% CI lower bound at least 75%, and reports mean Agatston-category accuracies exceeding 94% with lower bounds above 75%; it also reports no specific site count.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Automatic coronary-artery calcium plaque segmentation for downstream calcium scoring.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Segmentation and classification support for downstream calcium scoring; adjunctive information only and not a stand-alone diagnostic tool.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Non-contrast CT heart calcium-score studies from adults aged 30 and older, with GE or Siemens equipment or subsidiaries recommended; exclusions include cardiac devices/electrodes, established ischemic disease, and thoracic metallic devices.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
DICOM result files containing an automatic 3D coronary-calcification mask, vessel classification for LM/LAD/LCX/RCA, and Agatston category classification for downstream scoring; the device does not output the Agatston score directly or alter the original data.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Clinical use of adult calcium-score CT studies in medical imaging workflows.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Trained healthcare professionals responsible for patient-management decisions under standard of care.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Excluded patients include pre-existing cardiac devices/electrodes, established ischemic disease such as grafts, stents, or PTCA, and thoracic metallic devices. Use with GE or Siemens equipment or subsidiaries is recommended; other manufacturers are not recommended. The packet is internally inconsistent about gated status in a comparison paragraph, so gated support is not inferred beyond the non-contrast CT-heart indication.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA retrospective cohort study included 422 adults aged 30 and older with non-contrast calcium-score CT and heart coverage; ground truth used three annotators and majority voting, with at least 50% of ground-truth data from multiple U.S. locations. FDA testing used segmentation Dice, Agatston-category accuracy, vessel-classification Dice, precision/recall, and agreement analyses. The packet states acceptance criteria of at least 80% accuracy/Dice with a 95% CI lower bound at least 75%, and reports mean Agatston-category accuracies exceeding 94% with lower bounds above 75%; it also reports no specific site count.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA retrospective cohort study included 422 adults aged 30 and older with non-contrast calcium-score CT and heart coverage; ground truth used three annotators and majority voting, with at least 50% of ground-truth data from multiple U.S. locations. FDA testing used segmentation Dice, Agatston-category accuracy, vessel-classification Dice, precision/recall, and agreement analyses. The packet states acceptance criteria of at least 80% accuracy/Dice with a 95% CI lower bound at least 75%, and reports mean Agatston-category accuracies exceeding 94% with lower bounds above 75%; it also reports no specific site count.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

TeraRecon Cardiovascular.Calcification.CT regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K250288
  • Samplen=422
  • IndependenceIndependence not established

K250288

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K250288. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Non-contrast CT heart calcium-score studies from adults aged 30 and older, with GE or Siemens equipment or subsidiaries recommended; exclusions include cardiac devices/electrodes, established ischemic disease, and thoracic metallic devices.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K250288: TeraRecon Cardiovascular.Calcification.CT

  2. Routing

    Source context, not route validation: Containerized application on off-the-shelf hardware or a cloud platform; DICOM result files are viewable in DICOM-compliant systems and may be used by external viewers. Exact interfaces, versions, and current deployment configuration are not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K250288: TeraRecon Cardiovascular.Calcification.CT

  3. AI processing

    Source context, not route validation: The exact FDA package describes the algorithm as image processing software deployed as a containerized application (e.g., Docker container) that runs on off-the-shelf hardware or on a cloud platform. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "The TeraRecon Cardiovascular.Calcification.CT algorithm is an image processing software device that can be deployed as a containerized application (e.g., Docker container) that runs on off-the-shelf hardware or on a cloud platform." … "is a software as a medical device (SaMD) deployed as a containerized application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K250288: TeraRecon Cardiovascular.Calcification.CT

  4. Returned objects

    Source context, not route validation: DICOM result files containing an automatic 3D coronary-calcification mask, vessel classification for LM/LAD/LCX/RCA, and Agatston category classification for downstream scoring; the device does not output the Agatston score directly or alter the original data.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K250288: TeraRecon Cardiovascular.Calcification.CT

  5. Viewer/worklist/report

    Unresolved route: DICOM result files containing an automatic 3D coronary-calcification mask, vessel classification for LM/LAD/LCX/RCA, and Agatston category classification for downstream scoring; the device does not output the Agatston score directly or alter the original data.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K250288: TeraRecon Cardiovascular.Calcification.CT

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes the algorithm as image processing software deployed as a containerized application (e.g., Docker container) that runs on off-the-shelf hardware or on a cloud platform. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The TeraRecon Cardiovascular.Calcification.CT algorithm is an image processing software device that can be deployed as a containerized application (e.g., Docker container) that runs on off-the-shelf hardware or on a cloud platform." … "is a software as a medical device (SaMD) deployed as a containerized application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
Containerized application on off-the-shelf hardware or a cloud platform; DICOM result files are viewable in DICOM-compliant systems and may be used by external viewers. Exact interfaces, versions, and current deployment configuration are not established.
  • Exact FDA submission
  • Checked 2026-09-08
Security
TeraRecon announces it has been recognized as an ISO 27001:2022 certified company, maintaining an information security management system with documented processes for managing sensitive company information, HR processes, and IT systems; the announcement names TeraRecon's Intuition product and Eureka Clinical AI platform.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement; the certificate was not read (a certificate PDF is hosted on the same owning domain). Applicant name variants (TeraRecon Inc. with punctuation/case variants) are bridged via the identical distinctive name. Exact-release scope is not established.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for TeraRecon Cardiovascular.Calcification.CT; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K250288
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Heart/Coronary Arteries
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-10-23
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K250288 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K250288: TeraRecon Cardiovascular.Calcification.CT

    U.S. Food and Drug Administration - Published 2025-10-23 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. TeraRecon Cardiovascular.Calcification.CT model card (K250288)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K250288

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. TeraRecon: ISO 27001:2022 Certification Announcement

    TeraRecon - Published 2023-05-30 - Accessed 2026-10-27

    Scope: security

Research history

  1. K250288 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K242338

Cleerly LABS (v2.0)

Cleerly, Inc.

Authorized purpose: Assists trained professionals with coronary-vessel, lumen, vessel-wall, plaque and stenosis visualization and measurements from CCTA; it does not replace clinical judgment.

Modality
CT/CTA
Anatomy
Heart/Coronary arteries
Decision
2025-03-07
FDA-cleared K252029

AI-CVD

HeartLung Corporation

Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.

Modality
CT/CTA
Anatomy
Chest, abdomen, heart, lungs, liver, aorta, pulmonary artery, bone, muscle, and fat
Decision
2025-12-19
FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history